



Du jeudi 12 au
vendredi 13 Juin
2025

PALAIS DES CONGRÈS
D'ANTIBES JUAN-LES-PINS
FRANCE

23^{ème}

CONGRÈS INTERNATIONAL
DE GYNÉCOLOGIE
OBSTÉTRIQUE
& REPRODUCTION
DE LA CÔTE D'AZUR

Inscriptions et hébergements
directement sur

www.gynazur.eu

Tarif réduit jusqu'au 27 mars 2025

LOGISTIQUE
INSCRIPTIONS ET HOTELS

Sabrina PARRA
sparra@antipolis-events.com
Tél. : +33 (0)4 22 10 60 19

PARTENAIRES

Loraine MAUMY
lmaumy@antipolis-events.com
Tél. : +33 (0)4 22 10 60 24

COORDINATION
SCIENTIFIQUE

Pr André BONGAIN
gynazur@gmail.com


Réinjection de Tissu Graisseux & Dérivés: - Les étapes pour bien débuter.

Professeur Guy **MAGALON**

Marseille France

g.magalon@gmail.com

HISTORIC



FAT

1893

NEUBER G.A. 1850 – 1932 **GERMANY**

Fett transplantation, Verl.Dtsch.Ges.Chir. [1893](#), Long Vern 22:66



CZERNY V. 1842 – 1916 **GERMANY**

Czerny V. Drei plastische Operationen.3. Plastischer Ersatz der Brustdruse durch ein Lipom. Arch f Klin Chir 50:544-550, 1985

LEXER E. 1867 – 1937 **GERMANY**

Freie Fetttransplantation. Dtsch. Med.Wochenschr. [1910](#), 36:640



1984 - 1989

ILLOUZ Y.G. 1980 **FRANCE**

L'avenir de la réutilisation de la graisse après liposuction.

Rev. Chir. Est. **1984**, 36 (9)

L'avenir de la réutilisation de la graisse après liposuction.(suite)

Rev. Chir. Est. **1985**, 38 (10) : 19-22

Utilisation de la graisse aspirée pour combler les defects cutanés.

Rev. Chir. Est. **1985**, 40 : 13-20

The fat cell graft : A new technique to fill depressions

Plast.Reconstr.Surg. **1986**, 78 : 122-123

La sculpture chirurgicale par lipoplastie.

Perspective d'avenir : la réinjection ou transposition
autogène de la graisse aspirée. Paris, Arnette, **1988**

Present results of fat injection. Aesth.Plast.Surg. **1988**, 12 : 175-181

FOURNIER P. 1996 **FRANCE**

Liposculpture : Ma Technique (2ème édition) Paris, Arnette **1996**



1994

COLEMAN S.R.

1990 USA



- * The technique of periorbital lipoinfiltration
Op.Techn.Plast.Reconstr.Surg. 1994, vol 1, n°3
- * Lipoinfiltration of the upper lip white roll.
Aesth.Surg. 1994, vol 14, n°4
- * Long-term survival of fat transplants :
Controlled demonstrations.
Aesth.Plast.Surg. 1995, vol 19 : 421-425
- * Facial recontouring with lipostructure.
Clinics in Plast. Surg. 1997, vol 24 :347-367
- * Training Course , Marseille. 1998



Stromal Vascular Fraction - SVF



1964 **RODBELL M. et al.**

1969 **HOLLENBERG Ch et al.**



described Stromal Vascular Fraction (SVF) isolation from adipose tissue using enzymatic digestion

2001 **ZUC Patricia A.**

Multilineage Cells from Human Adipose Tissue:
Implications for Cell-Based Therapies

**PATRICIA A. ZUK, Ph.D.,^{1,2} MIN ZHU, M.D.,^{1,2} HIROSHI MIZUNO, M.D.,²
JERRY HUANG, B.S.,² J. WILLIAM FUTRELL, M.D.,³ ADAM J. KATZ, M.D.,³
PROSPER BENHAIM, M.D.,² H. PETER LORENZ, M.D.,²
and MARC H. HEDRICK, M.D.²**



Zuk et al, Tissue Engineering 2001

2013 **ZUC Patricia A.**

Adipose-Derived Stem cells in tissue Regeneration: A review
ISRN Stem Cells, 2013, Article ID 713959



2013

Emulsified Fat

Plastic and Reconstructive Surgery • October 2013

Nanofat Grafting: Basic Research and Clinical Applications

Patrick Tonnard, M.D.
Alexis Verpaele, M.D.
Geert Peeters, M.D.
Moustapha Hamdi,
M.D., Ph.D.
Maria Cornelissen, Ph.D.
Heidi Declercq, Ph.D.
Ghent and Brussels, Belgium

Background: The indications for fat grafting are increasing steadily. In microfat grafting, thin injection cannulas are used. The authors describe their experience of fat injection with even thinner injection needles up to 27 gauge. The fat used for this purpose is processed into “nanofat.” Clinical applications are described. Preliminary results of a study, set up to determine the cellular contents of nanofat, are presented.

Methods: Nanofat grafting was performed in 67 cases to correct superficial rhytides, scars, and dark lower eyelids. Three clinical cases are described. In


www.PRSJournal.com

see Video, Supplemental Digital Content 1,
<http://links.lww.com/PRS/A855>



2013

Mixture Fat Grafts and ASCs



Stig-Frederik Trojahn KOLLE

Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trial

Stig-Frederik Trojahn K lle, Anne Fischer-Nielsen, Anders Bruun Mathiasen, Jens J rgen Elberg, Roberto S Oliveri, Peter V Glovinski, Jens Kastrup, Maria Kirchhoff, Bo Sonnich Rasmussen, Maj-Lis M ller Talman, Carsten Thomsen, Ebbe Dickmeiss, Krzysztof Tadeusz Drzewiecki





THE LANCET


2013

20 millions ASCs / mL de graisse
= 650 millions d'ASCs !!!
Suivi sur 4 mois...

Findings 13 participants were enrolled, three of whom were excluded. Compared with the control grafts, the ASC-enriched fat grafts had significantly higher residual volumes: 23.00 (95% CI 20.57–25.43) cm³ versus 4.66 (3.16–6.16) cm³ for the controls, corresponding to 80.9% (76.6–85.2) versus 16.3% (11.1–21.4) of the initial volumes, respectively (p<0.0001). The difference between the groups was 18.34 (95% CI 15.70–20.98) cm³, equivalent to 64.6% (57.1–72.1; p<0.0001). No serious adverse events were noted.



- **PRODUCTS**
- **MEDICAL DEVICES**
- **TECHNIQUES**
 - **HARVESTING**
 - **MANUAL**
 - **ASSISTED**
 - **PREPARATION**
 - **DECANTATION**
 - **CENTRIFUGATION**
 - **FILTRATION**
 - **MECHANICAL PREPARATION**
 - **INJECTION**





Dr JC. GUIMBERTEAU



**Milli Fat
Microfat
Preparation of Fat**

**Mechanical
Preparation
Devices**

- P. Tonnard
 - Tulip®
 - Hy Nanofat®
 - Emulsfat®
- EMULSIFICATION
- Microlyser®
 - Adinizer®
 - Boost®
- MICRONIZATION
- Lipocube®
 - Lipogems®
 - ...

Enzymatic Preparation


ATMP

Advanced Therapy Medicinal Products

Mechanical Preparation

SVF
Stromal Vascular
Fraction

MSCs
Mesenchymal Stem Cells



>10µm

SVT
Stromal Vascular
Tissue
SVF Gel
Lipocondensation

SVF
Stromal Vascular
Fraction



Mixed Products

MILLI

Coleman's cannula



Khoury's cannula



Dimensions of Fat Lobules


$\geq 2\text{mm}$

MICRO


Sorensen's cannula




Magalon's cannula




$\leq 1\text{mm}$




Mechanical Stromal Vascular Tissue




Enzymatic Stromal Vascular Fraction



Adipose Tissue Stem Cell Culture




Adipocyte




Adipoblast



Lymphocyte




Macrophage




Fibroblast




**Endothelial
cell**



**Endothelial
progenitor cell**



Pericyte




**Mesenchymal
stem cell**

Big volume Fat Harvesting

General Anaesthesia

- Breast



- Buttock



MicroAire
PAL®
liposuction
system



Human Med
body-jet® devices



Alma Lasers



Lipolife™

Möller Medical



Workstation

Neosyd



Adimate





Small volume Fat Harvesting

Local Anaesthesia


• Face

PATIENT: (PATIENT #2) TOTAL VOLUME: 400cc


ITR² DATA
ANATOMIC PLACEMENTS & VOLUMES OF FAT

Pre-Skeletal Millifat Brows L: / R: / Dorsum 1cc Nasal Tip / Pyriforms L: 3cc / R: 3cc Lips U: 3cc / L: 2cc Mandibles L: / R: / Chin /	Suprapreosteal 	Deep Fat Compartments Below Muscle 	Millifat Temporals L: 4cc / R: 4cc SOOFs/Cheeks L: 3cc / R: 3cc Sup. Orbit Sulc / Buccal Fat L: 2cc / R: 2cc	Microfat Forehead L: 5cc / R: 5cc Temporals L: / R: / Infraorbitals L: 2cc / R: 2cc Cheeks L: / R: / Nasolabial folds L: / R: / Marionette Lines L: 3cc / R: 2cc Chin /	Superficial Fat Compartments, Above Muscle 	Rhytidium, Dermis, and/or Superficial Fat Compartments 	Nanofat Tear Trough L: / R: / Perioral Region Cheeks L: / R: / Microneedling (Face, Neck, Chest) Biocream (200 cc)
---	---	--	---	--	--	--	--

• Hand



• Genital area



PROTOCOL Local Anaesthesia

Tumescent ANESTHESIA

Klein fluid formula:

- 500 mL of saline solution

- 25 mL of 1% lidocaine
250mg

- 0,5 mg of epinephrine

6ml of NaH_2CO_3
Sodium bicarbonate

Cytori fluid formula:

300ml Fluide
150ml Graisse


- 250 mL of Lactated Ringer's solution

- 10 mL of 1% lidocaine
100mg

- 0,5 mg of epinephrine



- maximum safe dosage
45mg/kg



- safe dosage
1mg/l

I - MILLI - Sydney COLEMAN



HARVESTING





2,23mm



PURIFICATION




3000 RPM - 3 min -1200G



REINJECTION



1mm incision with a #11 surgical blade



17G cannula (O.D.=1,50mm)

Distal opening 2 mm


1 ml LUER LOCK syringe



S.R.COLEMAN's placement cannula : 17 G

Cannula creates several tunnels

Training course on
FAT REINJECTION
"Autologous Fat Grafts"
 with
Sydney R. COLEMAN M.D.
 (New York-USA)
"Utilisation du tissu graisseux autologue"
 en Chirurgie Esthétique et Réparatrice






15 & 16 Mai 1998
MARSEILLE

COORDINATION SCIENTIFIQUE
 Pr G. MAGALON - Dr R. AMAR
 Marseille


ORGANISATION
 Agence ATOUTCOM
 Marseille

www.lipostructure.com




Sydney R. COLEMAN, M.D.

2009





Edited by
Sydney R. Coleman




Translated
into Chinese

2018






2022



II - MICRO material


HARVESTING CANNULA

$\varnothing=2\text{mm}$ – 14 Gauge – 130mm



FILTRATION BAG CLOSED SYSTEM

$S=0.58\text{ mm}^2$





INJECTION CANNULA



$\varnothing=0.8\text{mm}$ – 21 Gauge – 40mm

FILTRATION BAG





Mesenchymal Stromal Cells (MSC)

Hitomi Eto, M.D.
Harunosuke Kato, M.D.
Hirotaka Suga, M.D.
Noriyuki Aoi, M.D.
Kentaro Doi, M.D.
Shinichiro Kuno, M.D.
Kotaro Yoshimura, M.D.
Tokyo, Japan

The Fate of Adipocytes after Nonvascularized Fat Grafting: Evidence of Early Death and Replacement of Adipocytes

Plastic and Reconstructive Surgery • May 2012




Fig. 6. Conclusive schema for three zones of the grafts. The most superficial zone is the “surviving zone,” which is less than 300 μm thick. In the surviving zone, both adipocytes and adipose-derived stromal cells (ASCs) survive. The second zone is the “regenerating zone,” the thickness of which varies depending on the microenvironmental conditions such as vascularity of and attachment to the surrounding tissue. In this zone, adipocytes die as early as day 1, but adipose-derived stromal cells survive and provide new adipocytes to replace the dead ones. The most central zone is the “necrotic zone,” where both adipocytes and adipose-derived stromal cells die, no regeneration is expected, and the dead space will be absorbed or filled with scar formation.

Comparison of Three Different Fat Graft Preparation Methods: Gravity Separation, Centrifugation, and Simultaneous Washing with Filtration in a Closed System

Min Zhu, M.D.
Steven R. Cohen, M.D.
Kevin C. Hicok, M.S.
Rob K. Shanahan, B.S.
Brian M. Strem, Ph.D.
Johnson C. Yu, B.S.
Douglas M. Arm, Ph.D.
John K. Fraser, Ph.D.

San Diego, Calif.

Background: Successful long-term volume retention of an autologous fat graft is problematic. The presence of contaminating cells, tumescent fluid, and free lipid in the graft contributes to disparate outcomes. Better preparation methods for the fat graft before transplantation may significantly improve results. **Methods:** Subcutaneous fat from 22 donors was divided and processed using various graft preparation methods: (1) no manipulation control, (2) gravity separation, (3) Coleman centrifugation, and (4) simultaneous washing with filtration using a commercially available system (Puregraft; Cytos Therapeutics, Inc., San Diego, Calif.). Fat grafts from various preparation methods were examined for free lipid, aqueous liquid, viable tissue, and blood cell content. Adipose tissue viability was determined by measuring glycerol release after agonist induction of lipolysis. **Results:** All test graft preparation methods exhibited significantly less aqueous fluid and blood cell content compared with the control. Grafts prepared by washing with filtration exhibited significantly reduced blood cell and free lipid content, with significantly greater adipose tissue viability than other methods. **Conclusion:** Washing with filtration within a closed system produces a fat graft with higher tissue viability and lower presence of contaminants compared with grafts prepared by alternate methods. (*Plast. Reconstr. Surg.* 131: 873, 2013.)



Effect of Washes and Centrifugation on the Efficacy of Lipofilling With or Without Local Anesthetic

Anne-Claire Girard, PhD*
Sophie Mirbeau, MSc*
Lydie Gence, MSc*
Vincent Hivernaud, MSc*†
Pierre Delarue, MD‡
Olivier Hular, MD§
Franck Festy, PhD*
Regis Roche, PhD*

Background: Among the different parameters that influence fat graft survival and lipofilling success, the use of local anesthetic and the way to process the fat before injection have often been pointed out. Likewise, we evaluated different techniques for processing adipose tissue before its injection and analyzed the quality of the grafts.

Methods: Adipose tissue from the same patient was gently harvested from one side of the abdomen after infiltration of a tumescent solution without lidocaine and from the other side of the abdomen using a tumescent solution containing lidocaine 2%. Harvested tissue was prepared with different protocols, from simple decantation to advanced protocols including single or multiple washes and centrifugations. Each type of processed adipose tissue was then injected subcutaneously into immunodeficient mice. Adipose grafts were collected after 1 month and analyzed by histology with a detailed scoring method.

Results: After lidocaine use, decantation protocol led to adipose grafts of poor quality with high resorption rate and oil vacuole formation. Larger grafts were obtained after centrifugation, but centrifugation alone resulted in increased fibrosis and necrosis, with or without the use of lidocaine. Finally, multiple washes and centrifugations greatly improved the quality of the lipografts.


Conclusions: Centrifugation alone is not sufficient and must be associated with multiple washes to improve graft quality. This article aims to provide further evidence of lidocaine and washing/centrifugation effects in fat grafting to provide easy tips aimed at ensuring graft efficiency with a long-term clinical outcome. (*Plast Reconstr Surg Glob Open* 2015;3:e496; doi: 10.1097/GOX.0000000000000465; Published online 27 August 2015.)

III - MECHANICAL PREPARATION OF FAT SVT Stromal Vascular Tissue


EMULSFAT



HY TISSUE -NANOFAT



TULIP




LIPOCUBE



ADINIZER



Mini BOOST



MICROLYSER




Choose a Mechanical Preparation Kit

- Emulsification: **shear force**



- Micronization



- Final size with or without filter:

2400 μ 1200 μ 600 μ 400 μ 200 μ 120 μ 100 μ










No enzyme - Mechanical production
 Inside Operating room
 SVF cells – Oil – Adipocytes ?

2024

BIOLOGICAL QUALITY OF SVF FROM NANOFAT OBTAINED WITH COMMERCIAL DEVICES



	Viability 	Recovery yield  Viable nucleated cells / cc of AT	Cellular composition 
Higher device	91.8 ± 8.5 %	838 250 ± 636 014	Regenerative cells 49.7 ± 20.4 % Leukocytes 28.9 ± 10.5 %
Lower device	83.6 ± 12.4 %	95 550 ± 96 337	Regenerative Cells 34.3 ± 29.4 % Leukocytes 52.6 ± 11.4 %



ADIPOCYTES IN ALL
 EMULSIFIED FAT +++

MECHANICAL PREPARATION

I. LOCATION AND DEPTH OF SAMPLING

II. INFILTRATION OR NOT ?

III. SIZE AND QUALITY OF THE SYRINGES

IV. CANNULAS

SIZE OF THE HARVESTING CANNULA

SIZE AND NUMBERS OF HOLES

SHARP MICROPORTS

V. PURIFICATION STEP OF FAT:

DECANTATION

CENTRIFUGATION

FILTRATION

VI. KIT CHOICE:

FAT EMULSIFICATION

FAT MICRONIZATION

VII. SIZE OF THE FINAL FILTER

**WE NEED VERY PRECISE
PROTOCOL WITH
BIOLOGICAL
CHARACTERIZATION OF THE
FINAL PRODUCT**

**Each modification changes
the final product**

IV – STROMAL VASCULAR FRACTION

ADIPOSE DERIVED REGENERATIVE CELLS - ADRCs

- **MANUAL TREATMENT** in a clean room or laboratory according to the cGMP
- **AUTOMATIC TREATMENT** using a CE marked device, labeled to replace, repair, reconstruct or increase soft tissue defects.



CELUTION®




GID TECHNOLOGY™



ACS™


Adipose-Related Terminology



Aspirated
Adipose Tissue

Cell Type	Frequency
Adipocytes	~50%
Blood Vessel Cells	25%
Blood Cells & Macrophages	25%
Stem Cells	~1%


Enzyme
Digestion



Stromal
Vascular Fraction

Cell Type	Frequency
Adipocytes	0%
Blood Vessel Cells	~50%
Blood Cells & Macrophages	~50%
Stem Cells	1-2%

Cell
Culture



ADSCs

Cell Type	Frequency
Adipocytes	0%
Blood Vessel Cells	0%
Blood Cells & Macrophages	0%
Cultured ADSCs	100%

LEGAL ASPECTS RELATING TO THE STEM CELL CRITERIA FOR ATMPs

10.12.2007

EN

Official Journal of the European Union

L 324/121

REGULATION (EC) No 1394/2007 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 13 November 2007
on advanced therapy medicinal products and amending Directive 2001/83/EC
and Regulation (EC) No 726/2004
(Text with EEA relevance)

ATMP : Advanced Therapy Medicinal Products

Cells or Tissues have been subject to **substantial manipulation**, so that biological characteristics, physiological functions or structural properties relevant for the intended indication or regeneration are achieved

OR

Cells or Tissues are **not intended to be used for the same essential function** in the recipient as in the donor (**non homologous use**)

MTI : Médicaments de Thérapie Innovante



STERILITY TESTING



⇒ AEROBIC and ANAEROBIC inoculation




⇒ INCUBATION : 10 days

⇒ Recommendations for sampling

Final product volume (ml)	Inoculum volume
> 10 ml	1%
1 < v < 10ml	100 µl


GRAM staining on harvested adipose tissue

prior to delivery to patient (released quality control)




CYTOMETRY

Lymphocytes
(Discrimination CD45+
size/structure)




Monocytes
+granulocytes
(Discrimination CD45+
size/structure)




Size (FCS)


Mesenchymal
stem cells
(CD45-
/CD34+/CD90+/CD146-)



Endothelial
Progenitor cells
(CD45/CD34bright/
CD146dim/CD90+)



Endothelial cells
(CD45-
/CD34dim/CD146bright/CD90+)



CELL NUMERATION AND VIABILITY

Many methods are available and validated


Choice of automatically method by Nucleocounter NC-100® :



- 15 minutes
- Sample : 100µl
- Measured in duplicate
- Propidium iodide
- 2 steps :
 - Dead cell count
 - Total cell count

⇒ SCLERADEC trial : ≥ 80% viability for the batch release

« The current gold standard for enumerating stem cells that are members of the ADSC/MSC family is the CFU-F assay in which the ability of the cells to proliferate is determined. Individual stem cells proliferate to form colonies that are counted. This process takes 10-14 days. » John FRASER



Clonogenic Assay: Colony Forming Unit-Fibroblast
As recommended by the International Society for Cellular Therapy



Enzymatic production
ATMPs status
Heterogeneous suspension of cells – NO ADIPOCYTES

GMP PRODUCTION & CHARACTERIZATION OF STROMAL VASCULAR FRACTION

RESEARCH

Open Access

Inter-center comparison of good manufacturing practices-compliant stromal vascular fraction and proposal for release acceptance criteria: a review of 364 productions



Pauline François^{1,2}, Giulio Rusconi^{3,4}, Laurent Arnaud⁵, Luca Mariotta³, Laurent Giraudo¹, Greta Minonzio³, Julie Veran¹, Baptiste Bertrand⁶, Chloé Dumoulin¹, Fanny Grimaud¹, Luc Lyonnet⁵, Dominique Casanova⁶, Camille Giverne⁷, Audrey Cras⁸, Guy Magalon⁹, Françoise Dignat-George^{2,5}, Florence Sabatier^{1,2,9}, Jeremy Magalon^{1,2,9*†} and Gianni Soldati^{3†}






2021



294 SVF batches of therapeutic grade produced at **SSCF**



70 SVF batches of therapeutic grade produced at **APHM**

	Viability 	Recovery yield Viable nucleated cells / cc of AT 	Cellular composition 
 N= 294	89.3 ± 4.3 %	254 000 ± 120 000	Regenerative cells 70.1 ± 13.1 % Leukocytes 29.8 ± 11.4 %
 N= 70	84.2 ± 6.0 %	225 000 ± 111 000	ASC 54,8 ± 14.0 % Leukocytes 45.2 ± 16.2 %

V – MIXTURES


CAL :
CELL ASSISTED LIPOTRANSFER
A POPULAR PROCEDURE...



ADIPOSE TISSUE





PRP



SVT
Stromal
Vascular
Tissue



SVF



Cultured
Stem Cells
(ASCs)

EASY
FAST
ECONOMICALLY VIABLE

= Promoting
Fat Engraftment ?

DIFFICULT
LONG
EXPENSIVE



VI – INDICATIONS

CELLULAR THERAPIES

❖ Volumizing effect Fat tissue: MILLI - MICRO

- Replacement of missing tissues with autologous fat

❖ Regenerative effect Fat tissue:

- Mechanical preparations

STROMAL VASCULAR TISSUE – EMULSIFIED or MICRONIZED FAT

- Modified emulsified fat - SVF Gel

- Lipocondensation

- Enzymatic preparation - STROMAL VASCULAR FRACTION

❖ Regenerative effect Platelet Rich Plasma

...

RULES FOR LIPOFILLING IMPROVEMENT

1 – INFILTRATION

*Careful of lidocaine !

2 – LIPOSUCTION

Small holes cannula = better vascularization

Low negative pressure = less than 0.5 atm or 380 mmHg

3 – FAT PREPARATION

Active filtration: removes

- Tumescant fluid, Free lipids, Blood cells ...

Washes are really important (even without lidocaine)

4 – FAT INJECTION

Injection of small quantities in different layers

VII – RESULTS

VOLUMIZING

IMMEDIATE EFFECT (2-6 months)

- MILLI
- MICRO

REJUVENATING

DELAYED EFFECT (12 months)

➤ MECHANICAL PREPARATIONS :

EMULSIFICATION / MICRONIZATION : “NANOFAT” **STROMAL VASCULAR TISSUE**

➤ MECHANICAL PREPARATIONS :

EMULSIFICATION / MICRONIZATION + CENTRIFUGATION : “NON ENZYMATIC SVF”

➤ ENZYMATIC PREPARATIONS : **STROMAL VASCULAR FRACTION**

CONCLUSION

- Cell Therapy products are manifold, and their preparations require rigorous protocols.
- Regenerative surgery is a major issue.
- Surgeons need to know the products and techniques available and choose indications.
- Advanced Therapy Medicinal Products (ATMP) with substantial manipulations are subject to very strict regulation.
- Evolution:
 - ❑ From Enzymatic Stromal Vascular Fraction to Mechanical Modified:
 - Stromal Vascular Tissue: Emulsified Fat - Micronized Fat
 - Mechanical Stromal Vascular Fraction
 - ❑ Enzymatic SVF or Stem Cells systemic use
 - ❑ Stem Cells Expansion System
 - ❑ Allogenic Stem Cells
 - ❑ Cryopreservation
 - ❑ Exosomes



Save the Date

REGENERATIVE MEDICINE & SURGERY

*HOW TO SET UP A REGENERATIVE
SURGERY STRUCTURE ?*

FRIDAY, NOVEMBER 14TH, 2025
CLINIQUE GENOLIER-SWITZERLAND

ORGANIZING COMMITTEE

Guy Magalon
Sophie Menkes

GENERAL ORGANIZATION
AToutCom Event Agency
med-regenerative@atoutcom.com
www.atoutcom.com

